BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weijer C, Goldstein CE, Taljaard M. TwiC or treat? Are trials within cohorts ethically defensible? Clin Trials 2018;15:21-4. [PMID: 29250989 DOI: 10.1177/1740774517746622] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Dal-Ré R. COVID-19 drug research and the cohort multiple randomised controlled trial design. Eur Respir J 2022:2200746. [PMID: 35896204 DOI: 10.1183/13993003.00746-2022] [Reference Citation Analysis]
2 Henderson GE, Rennie S, Corneli A, Peay HL. Cohorts as collections of bodies and communities of persons: insights from the SEARCH010/RV254 research cohort. Int Health 2020;12:584-90. [PMID: 33165552 DOI: 10.1093/inthealth/ihaa060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Nicholls SG, Carroll K, Hey SP, Zwarenstein M, Zhang JZ, Nix HP, Brehaut JC, McKenzie JE, McDonald S, Weijer C, Fergusson DA, Taljaard M. A review of pragmatic trials found a high degree of diversity in design and scope, deficiencies in reporting and trial registry data, and poor indexing. J Clin Epidemiol 2021;137:45-57. [PMID: 33789151 DOI: 10.1016/j.jclinepi.2021.03.021] [Reference Citation Analysis]
4 Young-Afat DA, Gal R, Gerlich S, Burbach JPM, van der Velden JM, van den Bongard DHJG, Intven MPW, Kasperts N, May AM, van der Graaf R, van Gils CH, Verkooijen HM. Oncology patients were found to understand and accept the Trials within Cohorts design. J Clin Epidemiol 2021;130:135-42. [PMID: 33130236 DOI: 10.1016/j.jclinepi.2020.10.015] [Reference Citation Analysis]
5 Miller DG, Kim SYH, Li X, Dickert NW, Flory J, Runge CP, Relton C. Ethical Acceptability of Postrandomization Consent in Pragmatic Clinical Trials. JAMA Netw Open 2018;1:e186149. [PMID: 30646316 DOI: 10.1001/jamanetworkopen.2018.6149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Chappell R. Comment on Vickers et al. Clin Trials 2019;16:214-5. [PMID: 30317868 DOI: 10.1177/1740774518806868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Kim SY, Flory J, Relton C. Rejoinder. Clin Trials 2018;15:27-8. [PMID: 29400564 DOI: 10.1177/1740774517746629] [Reference Citation Analysis]
8 Vickers A, Young-afat D, Ehdaie B, Kim SY. Rejoinder. Clinical Trials 2017;15:25-6. [DOI: 10.1177/1740774517746638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]